France won’t pay for weight loss drug Wegovy. What about other European countries?
France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on euronews
WeightWatchers to offer compounded version of Novo Nordisk's weight-loss drug
WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of its weight-management programs. Soaring demand for weight-loss drugs such as Wegovy and Eli Lilly's Zepbound,
Ozempic, Wegovy maker Novo Nordisk questioned over high cost of weight-loss drugs
U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North Carolina cut the weight-loss drugs from its state health plan.
WeightWatchers stock price skyrockets on news that it will offer a compounded GLP-1 weight-loss drug like Wegovy
The embattled diet brand said it is adding a compounded weight-loss drug in accordance with FDA rules and manufacturing standards. WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs,
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over dieting.
What Is Wegovy? Doctors Explain the Injectable Weight-Loss Drug
While medications like Ozempic originally dominated the weight-loss space, Wegovy is another injectable prescription weight-loss drug worth knowing about. When properly prescribed, it's been shown to help people lose weight and keep it off,
Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India
Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...
Wegovy and Zepbound rival targeting ‘next generation' of obesity drugs, Zealand Pharma CEO says
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
Novo Nordisk: Mounting Challenges
Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...
BioSpace11h
Pressure Mounts on Novo Nordisk’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...
Novo Nordisk settles US patent fight with Viatris over Ozempic
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
CBS News17d
Novo Nordisk CEO grilled for steep cost of Ozempic and other weight loss drugs
The drug company has set prices for Ozempic and Wegovy much higher than in other countries. The committee found earlier this year that Novo Nordisk charges Americans with diabetes $969 a month ...
USA Today18d
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Senators grilled the top executive of Novo Nordisk over why the Danish company charges Americans far more for the blockbuster weight-loss drug Wegovy and diabetes drug Ozempic than it does ...
FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears
Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...
Novo Nordisk A/S (NVO) Bullish on Wegovy Launch in International Markets
We recently published a list of Renaissance Technologies Portfolio: 10 Best Stocks To Buy. In this article, we are going to ...